RecruitingNCT06229860
Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts w/Chronic Myeloid Leukemia
Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Patients With Chronic Myeloid Leukemia
Sponsor
University of California, Irvine
Enrollment
75 participants
Start Date
Jan 25, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
This is an observational pilot study to examine the association between a patient's personality and adherence to tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
Eligibility
Min Age: 18 Years
Inclusion Criteria6
- years of age or older
- Diagnosed with chronic myeloid leukemia (CML) and in the chronic phase (CML-CP)
- Currently being treated with one of four cancer medications - imatinib, dasatinib, bosutinib, or nilotinib
- A patient at the UCI Chao Family Comprehensive Cancer Center (CFCCC), or
- A member of a patient support group organized by the CML Buster Foundation
- Do not meet any of the criteria listed under "Exclusion Requirements"
Exclusion Criteria2
- Unable to read and speak English
- Impaired decisional capacity to consent
Interventions
OTHERInterview
In-person interview with the study coordinator to complete study questionnaire.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06229860
Related Trials
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
NCT0699467611 locations
Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
NCT062367241 location
ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase
NCT050078731 location
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
NCT05334069740 locations
Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
NCT068177201 location